CFDE Data Portal | Search LINC01931

	Label	Description
	LINC01931 Gene (Entity type)	ENSG00000162947 - long intergenic non-protein coding RNA 1931
	GSE146358 dopamine 5 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE182150 KIT LSD1 MYC inhibition 2 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE159678 hydroxychloroquine 4 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE178267 vemurafenib 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE144843 GSE144844 SMARCA2 SMARCA4 knockdown 5 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE230174 glycerol 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE139685 MI-2 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GTEx Bladder 20-29 vs 40-49 Up Gene Set (Entity type)	A Gene Set from GTEx
	GTEx AdrenalGland 20-29 vs 30-39 Up Gene Set (Entity type)	A Gene Set from GTEx

LINC01931

ENSG00000162947 - long intergenic non-protein coding RNA 1931

GSE146358 dopamine 5 v 1 human up

A Gene Set from LINCS

GSE182150 KIT LSD1 MYC inhibition 2 v 7 human up

A Gene Set from LINCS

GSE159678 hydroxychloroquine 4 v 7 human dn

A Gene Set from LINCS

GSE178267 vemurafenib 2 v 0 human up

A Gene Set from LINCS

GSE144843 GSE144844 SMARCA2 SMARCA4 knockdown 5 v 2 human dn

A Gene Set from LINCS

GSE230174 glycerol 0 v 1 human up

A Gene Set from LINCS

GSE139685 MI-2 1 v 3 human up

A Gene Set from LINCS

GTEx Bladder 20-29 vs 40-49 Up

A Gene Set from GTEx

GTEx AdrenalGland 20-29 vs 30-39 Up

A Gene Set from GTEx

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.